Canadian Hospital Specialties Limited Joins AdvaMed®, the World’s Leading Medical Technology Trade Association

“The Insight Series: AI & Digital Health” features industry experts answering key questions to help inform policymakers and the public about how AI is shaping the future of care delivery. Our latest edition features Julia Strandberg, Executive Vice President, Chief Business Leader, Connected Care at Philips.

WASHINGTON—AdvaMed® announced today that nominations for its 2025 Lifetime Achievement Award as well as the AdvaMedDx Lifetime of Leadership & Service Award and theAdvaMed® Imaging Röntgen Award are open through April 10. All three of these annual awards will be presented during The MedTech Conference, Oct.18-21, 2026, in Boston. 

TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment. The technology received Breakthrough Device designation from the FDA and is designed to enhance surgeons’ ability to detect difficult-to-see cancer during breast-conserving surgery and potentially reduce the need for re-operations.

Watch AdvaMed’s® exclusive member-only webinar featuring a direct dialogue with CMS Innovation Center leadership on the newly released ACCESS & TEMPO Model. Attendees will gain critical insights into model performance metrics, payment pathways, and opportunities for the MedTech industry.

Scott Whitaker, president and CEO ofAdvaMed®, the world’s largest trade association representing medtech innovators, released the following statement after Fridays’ Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here. 

The U.S. Supreme Court recently marked a significant shift in the tariff landscape, learn what that means for your organization.

February is American Heart Month—a time to spotlight cardiovascular disease and highlight innovations that can improve patient outcomes. For the medtech community, it’s an opportunity to address persistent gaps in care through technology, data, collaboration, and policy advancement. Despite progress in treating heart conditions, sleep disorders—especially sleep apnea—remain a significant and underrecognized contributor to poor cardiovascular outcomes.1 Tackling this issue requires clinical awareness and supportive policies for timely diagnosis, coverage, and care beyond traditional settings.

WASHINGTON—AdvaMed, the MedTech Association®, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker,AdvaMed® president and CEO, made the following comment on the renewal.